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Abstract
Gluten content from barley, rye, wheat and in certain oat varieties, must be avoid in individuals with celiac disease. In most
of the Western countries, the level of gluten content in food to be considered as gluten-free products is below 20 parts per
million measured by ELISA based on specific anti-gluten peptide antibody. However, in beverages or food suffering
complex hydrolytic processes as beers, the relative proportion of reactive peptides for celiac patients and the analytical
techniques may differ, because of the diversity of the resulting peptide populations after fermentations. A beer below 20
parts per million of gluten but yet detectable levels of gluten peptides by anti-gliadin 33-mer antibodies (G12 and A1) was
analyzed. We identified and characterized the relevant peptides for either antibody recognition or immunoactivity in celiac
patients. The beer was fractionated by HPLC. The relative reactivity of the different HPLC fractions to the G12/A1 antibodies
correlated to the reactivity of peripheral blood mononuclear cells isolated from 14 celiac individuals. Peptides from
representative fractions classified according to the relative reactivity to G12/A1 antibodies were identified by mass
spectrometry. The beer peptides containing sequences with similarity to those of previously described G12 and A1 epitopes
were synthesized and confirmed significant reactivity for the antibodies. The most reactive peptides for G12/A1 also
confirmed the highest immunogenicity by peripheral blood mononuclear cell activation and interferon c production from
celiac patients. We concluded that preparative HPLC combined with anti-gliadin 33-mer G12/A1 antibodies were very
sensitive and specific methods to analyze the relevant immunogenic peptides in hydrolyzed gluten.
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Introduction
Celiac disease (CD) is the most common food intolerance in
Western countries, with an estimated prevalence that may rise up
to 1% in the Caucasian population [1]. CD can be considered as
the intolerance of genetically predisposed individuals to gluten
polypeptides from wheat, rye, barley and to lower extend, certain
oat varieties [2–4]. Gluten is a complex of storage proteins that
contains high amounts of the amino acids glutamine, glutamic acid
and proline [5]. As a consequence, these proteins are poorly
degraded by the gastrointestinal enzymes and remain as relatively
large peptides when entering the small intestine. The ability of
gluten proteins to resist degradation was suggested to be one
reason for their harmful effect on susceptible people [6]. In celiac
individuals, immunogenic gluten peptides are deamidated by
tissue transglutaminase which association generates potent auto-
antigens. These biochemical interactions elicit a T-cell mediated
pathological response which consequences are the lymphocytary
infiltration of the intestinal epithelia and the destruction of
intestinal villi. This last effect makes CD patients to suffer from
malabsorption and malnutrition that may lead to diarrhea,
constipation, iron-deficiency anemia, osteoporosis, dermatitis
herpetiformis and even neurological disorders [7–9].
The only treatment for CD is a life-long strict gluten-free diet
(GFD), which normally leads to a complete remission of the
symptoms and mucosal histology [1]. However, a GFD is difficult
to maintain since this is a very common food additive. National
public organizations and international institutions, as Current
Codex Alimentarius and Food and Drug Administration (FDA),
propose immunological methods based on antibodies against
specific gluten peptides as feasible and reliable methods to ensure
the absence of gluten from barley, wheat and rye in food and
beverages [10,11]. The use of antibodies specific to epitopes
directly associated to the immunogenicity of the gluten peptides
may reduce those cases of underestimation or overestimation of
relevant gluten peptide content. Methods based on the antibodies
for the immunogenic 33-mer peptide -G12 and A1- have been
accumulating evidences for the detection of the dominant gluten
immunogenic peptides for celiac patients in the food [2,12–14].
Hydrolyzed gluten food or beverages could be the kind of samples
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where the measured gluten content could mostly differ from the
celiac immunogenicity depending on the target sequences to be
detected.
In a recent report, we examined the levels of gluten peptides
equivalent to one of the most immunoactive protease-resistant
gliadin 33-mer in 100 Belgian beers, using immunochromato-
graphic (IC) lateral flow test with G12 and A1 antibodies [14]. The
G12/A1 reactivity of beer HPLC fractions correlated to the
presence of previously described T-cell reactive epitopes. In order
to characterize low abundant reactive beer peptides to G12/A1
immunological methods, we have examined a beer legally
classified as ‘gluten-free’ because the net content of gluten was
below 20 parts per million (ppm) but with detectable levels
indicating trace quantities. We have identified and determined the
relevance of the immunoactive peptides in beer detectable by
G12/A1 IC-strips and G12 competitive ELISA. We have
sequenced peptides in HPLC fractions enriched in reactivity to
G12/A1 IC-strips and some of them synthesized. The most
reactive peptides to G12/A1 also showed the highest reactivity to
peripheral blood mononuclear cells (PBMCs) proliferation and
interferon c (INF-c) production from celiac patients.
Materials and Methods
Anti-gliadin 33-mer moAbs and peptides
Horseradish peroxidase (HRP) conjugated G12 and A1 moAbs
(G12-HRP and A1-HRP) and the 33-mer peptide were obtained
from Biomedal SL (Sevilla, Spain). The peptides PP 24.1
(PQPQQPQLPFPQQPQQPFPQPQQP), PP 24.2 (PQPQLPF-
PQQPQQPFPQPQQPQQP), PP 24.3 (PQPQQPQLPFPQQ-
PFPQPQQPQQP), PP 22.1 (PQQPQLPFPQQPFPQPQQ-
PQQP), QP 22.2 (QPQQPFPLQPQQPFPQQPPQQP), QP 7.1
(QLPYPQP), QP 7.2 (QQPFPQP), QQ 7.3 (QLPFPQQ), QQ 7.4
(QQPFPQQ), QQ 7.5 (QQPFPLQ), QY 6.1 (QPQLPY), QF 6.2
(QPQLPF), QF 6.3 (QPQQPF), and QQ 6.4 (QPQQPQ) were
supplied by Biomedal SL (Sevilla, Spain).
Beer protein fractions
Sample barley beer (type Strong Ale) was extracted using UGES
according to the instructions of the manufacturer (Biomedal SL,
Sevilla, Spain). Beer was separated into different fractions by
reversed-phase HPLC (RP-HPLC) on a semi-preparative C18
column and, next, each fraction was separated by RP-HPLC on
an analytical C18 column [14].
MoAbs G12/A1 immunochromatographic test
The assay was carried out with the GlutenTox sticks kit
according to the instructions of the manufacturer (Biomedal SL,
Sevilla, Spain). Beer fractions were diluted (1:10 to 1:300) in the
buffer solution provided and the gluten content was tested. The
test sticks were dipped into the solution (300 ml) for 10 min before
being removed and allowed to air dry.
Enzyme-linked immunosorbent assay
Maxisorp microtitre plates (Nunc, Roskilde, Denmark) were
coated with gliadin solution (Sigma, St Louis, MO, USA) and
incubated overnight at 4uC. The plates were washed with
phosphate-buffered saline (PBS) containing 0.05% Tween 20
and blocked with 5% non-fat dry milk in PBS for 1 h at room
temperature (RT). 33-mer peptide was used as standard. Serial
dilutions of peptides were made in PBS-bovine serum albumin
(BSA) 3%, to each of which was added G12-HRP or A1-HRP
antibody solution [14]. The samples were pre-incubated at RT,
and then added to the wells. After 30 min of incubation at RT, the
plates were washed and substrate solution (TMB, Sigma) was
added. The reaction was stopped with 1 M sulphuric acid, and the
absorbance at 450 nm was measured (microplate reader
UVM340; Asys Hitech GmbH, Eugendorf, Austria). Two separate
assays were performed, each with three repetitions.
Mass spectrometry
Beer fractions were analysed by nano LC-Electrospray Ion Trap
Mass Spectrometry (LC-ESI-IT-MS) (Ultimate 3000 nano HPLC,
Dionex, Sunnyvale, California, USA) and HCT Ultra ion-trap
Mass Spectrometry (Bruker Daltonics, Bremen, Germany). For
each fraction, 2 mg of total protein was reconstituted in nano
HPLC loading buffer (98% H2O milli-Q +2% acetonitrile +0.05%
TFA). The flow rate was 30 ml/min and the injection volume was
5 ml. Absorbance was monitored with the UV-visible detector at
214 nm and 280 nm. Eluting buffers were buffer A (H20 milli-Q +
0.1% formic acid) and buffer B (80% acetonitrile +20% H20 milli-
Q +0.1% formic acid). Proteins were eluted by applying the
following gradient conditions: isocratic elution with 4% B for
5 min; 4% to 40% B for 60 min; 40% to 95% B for 1 min; and
isocratic elution with 95% B for 7 min. Mass spectrometric data
were acquired in the automated data-dependent mode. Mass- and
charge-dependent collision energies were used for peptide
fragmentation. The 4 most-abundant ions were isolated and
fragmented using collision-induced dissociation (CID) (4s/MS/
MS spectrum). The spectra obtained were processed using
DataAnalysis 3.4 software (Bruker Daltonics, Bremen, Germany)
for analysis of raw data. Peptide masses obtained were exported to
BioTools 3.1 software (Bruker Daltonics, Bremen, Germany), and
the identification of proteins was carried out by searching for
Viridiplantae taxonomically restricted in the database of the
National Center for Biotechnology Information (NCBI), using
Mascot v.2.3.02 (www.matrixscience.com, Matrix Science, Lon-
don, UK).
Histological and serological analysis of subjects
Fourteen patients with biopsy-proven active CD were included
in this study. The diagnosis of CD was based on the positive
serology and compatible lesion in the duodenal biopsy according
to the criteria of Marsh [15] and confirmation of a clinical
response to gluten elimination from the diet. Subjects were
prospectively screened for CD using anti-endomysial antibodies
(AAEMs), tissue transglutaminase antibodies (AATGs) and CD-
specific human leukocyte antigen typing (HLA-DQ) (Table 1).
Venous blood was taken at the time of index biopsy. The
international standards for ethics (Helsinki declaration for studies
in humans) were followed and the study was approved by the
ethics committee of the ‘Virgen de las Nieves’ Hospital, Granada
(Spain). The written informed consent was obtained from the next
of kin or guardians on behalf of the minors enrolled in this study.
Cell proliferation analysis
The alcohol-soluble protein fractions were extracted from wheat
(Triticum aestivum) and rice (Oryza sativa) whole flour, positive and
negative control, respectively. These fractions were subjected to
pepsin, trypsin and chymotrypsin sequential digestion, as previ-
ously described by Real et al [3].
PBMCs which include lymphocytes (T cells, B cells and NK
cells), monocytes and dendritic cells, from patients with active CD
(n = 14) on gluten-containing diet were isolated from 6 ml of
heparinized blood by Histopaque gradient centrifugation, and
cultured at a density of 1x106 cells/ml in RPMI-1640 culture
medium. After 48 h, PBMCs were incubated with the different
samples and the proliferation was determined using a non isotopic
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assay based on the incorporation of 5-bromo-2-deoxyuridine
(BrdU) into the newly synthesized DNA according to manufac-
turer’s instruction (Millipore Chemicon, Temecula, California,
USA) [16,17]. Briefly, once the media containing BrdU is
removed, the cells are fixed and the DNA is denature. Then an
anti-BrdU mouse monoclonal antibody is added followed by and
HRP conjugated secondary antibody. Cells without BrdU reagent
added (background) and only tissue culture supernatant (blank)
were used as controls. The stimulation index (SI) value was
calculated by dividing the mean absorbance/10 at 450 nm after
stimulation by the mean absorbance of PBMCs exposed to the
culture medium alone (background) and divided by 10. All
cultures were performed in duplicate.
IFN-c production
Supernatants from PBMC culture were collected after 48 h and
stored at 280uC for IFN-c determination using a commercial
ELISA kit in accordance with the manufacturer’s instructions
(Thermo Scientific, Madrid, Spain). Standards were run on each
plate. Assay sensitivity was less than 2 pg/ml. All cultures were
performed in duplicate.
Statistical analysis
Anti-gliadin 33-mer ELISA. Peptide curves were obtained
by plotting percentage maximum absorbance against logarithm of
antigen concentration. The software package Sigma Plot 9.0
(Systat Software, Inc., Point Richmond, CA, USA) was used to
calculate IC50 and the cross-reactivity (CR) for each peptide. The
IC50 is defined as the concentration that produces a reduction of
50% in the peak signal in the ELISA. The CR was determined as
(IC50 of the peptide that presents the greatest affinity for the
antibody/IC50 of each peptide assayed) x 100.
Cell proliferation and IFN-c assays. Statistical analysis was
performed with the STATGRAPHICS program. Data are
expressed as mean 6 SD. When the interaction was statistically
significant, the differences between groups were examined by one-
factor analysis of variance (ANOVA). A Bonferroni-corrected t-test
was used to compare the individual means. A statistical probability
of p,0.05 was considered significant.
Results and Discussion
Immunoactive potential determination of beer fractions
Barley and wheat are the main cereals used in the production of
malt beer, the first step in the brewing. More than 40 different
proteases in addition to amylases are activated by malting. The
metabolic barley proteins that are released in the water solution
during mashing along with a much lower amount of hordeins, are
extensively hydrolyzed by the endogenous proteolytic enzymes
into short peptide fragments [18,19]. Due to their high content in
proline and glutamine, a heterogeneous mixture of peptides could
be resistant to proteolysis that could be toxic for CD patients.
Previous proteomic investigations support a strict consistence of
the beer proteome regardless of the brand under a qualitative
standpoint, while detectable differences appear confined to the
relative quantitative balance among protein components [20]. The
capacity to characterize a beer with low gluten peptide content
could then be expanded to any beer with superior concentration.
A Belgian commercial beer (Strong Ale) classified as potential
‘gluten-free’ (,20 ppm gluten) according to normative of Codex
Alimentarius, was selected as a representative sample for the
extensive immunological analysis [14]. To that purpose, this beer
was fractionated by RP-HPLC on a semi-preparative C18 column
and, next, each fraction was separated by RP-HPLC on an
analytical C18 column and assessed by G12/A1 IC-strips. This
beer presented 6 reactive fractions out of 18 total fractions, all of
them eluted at retention times .10.5 min [14]. Therefore, three
groups of fractions could be distinguished: a group with reactivity
.500-fold above the detection limit (E16 and E17), a group with
intermediate reactivity (E13-E15 and E18) and another group
comprising fractions that were not recognized by moAbs (E1-E12).
Taking into account that the range of gluten content was about
10 ppm by competitive G12 ELISA, the RP-HPLC technique
allowed to concentrate about 50-fold the reactive peptides in E16
and E17 fractions.
To test the correlation in G12/A1 reactivity and the immuno-
genicity of the different fractions in vitro, three of them were
selected based on the different level of reactivity to G12/A1
moAbs and were assessed by PBMC proliferation and IFN-c
response from peripheral blood isolated from celiac patients. The
clinical and immunological profiles of patients with CD are
presented in Table 1. Fraction E6 was chosen as representative of
non-reactive group, E15 represented the group with intermediate
reactivity and E17 that of the greatest reactivity. We found
significant differences in PBMCs proliferation with respect to
gliadin (positive control) in cultures incubated with E6
(SI = 7.360.9), which showed an activation of PBMCs slightly
higher than rice prolamins (negative control SI = 4.260.6)
(Figure 1A). E17 was the most reactive to G12/A1 IC-strips
and showed the highest increase in PBMCs proliferation
(SI = 18.662.1), and did not show significant differences with
respect to cultures incubated with positive control (SI = 20.161.8).
We found intermediate proliferation in cultures incubated with
E15 (SI = 14.561.2) (Figure 1A).
Release of IFN-c in the culture medium after the exposure of
celiac PBMCs to the different representative fractions was assessed
(Figure 1B). The highest values of IFN-c release were found in
supernatant of culture incubated with E17 (18.562.1 pg/ml) close
to the gliadin values (22.562.6 pg/ml). We found significant
differences with respect to positive control in cultures exposed to
E6, which induced a lower mean value of IFN-c (7.561.02 pg/
ml).
We selected one reactive fraction (E17) and one non-reactive
fraction (E6) in order to carry out the protein identification using
Mascot after mass spectrometry. The comprehensive list of peptide
fragments identified in the E6 and E17 fractions is shown in
Figures 1C and 1D, respectively. These dates confirm that the
sample beer contained a large number of partially degraded
fragments from the gluten proteome of barley and wheat. A total
of 7 different gluten proteins were identified in E6 and 14 in E17.
The peptides identified differed in both their amino acid
composition and length. It was interesting to know that in the
E17 fraction, the hordein and gliadin derived peptides identified
showed several motifs associated with the induction of CD. Among
them, we could find the ‘PQQPF’ sequence, described as one of
the main gliadin toxic motifs [21]. In that way, T-cell epitopes as
‘FPQQPQQPF’, ‘QQPQQPFPQ’, ‘QLPFPQQPQ’ and
‘QQPFPQQPQ’ were identified in different peptides present in
E17 but not in E6 [22–25].
Beers with gluten peptide content close to the quantitation limit
detected by the current analytical methods by antibodies (classified
according to international labelling rules as ‘gluten-free foods’, ,
20 ppm, for Codex Alimentarius and/or FDA), should be
analyzed in combination with in vitro immunological methods as
T-cell proliferative response.
In Vitro Reactivity of Immunoactive Peptides in a GF Beer
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Characterization of relative 33-mer epitopes in MS beer
peptides
Different research lines have shown that the reactivity of moAbs
G12 and A1 is correlated with the real potential immunotoxicity
T-cell-reactivity analysis and enzymatic detoxification of the
proteins showed that the signal of these antibodies was correlated
with the potential toxicity of the sample for celiac patients
[2,13,14,26,27]. Many of the peptides identified in E17 contained
runs Gln and Pro that may elicit an immunological response in
celiac patients. To confirm the capacity of the suspected peptides
of E17 fraction to be detectable by G12/A1 and their
immunogenicity for celiac, we chose different peptides with
similarities to epitopes for G12 (QPQ(L/Q)P(Y/F/Q)) and A1
(Q(L/Q)P(F/Y)P(Q/L)(P/Q). A total of five peptides of the
sequenced fragments with length of 22 or 24 amino acids
presented in the E17 were synthesized (Figure 2A). The affinity
of the moAbs to different peptides was determined by competitive
ELISA using a standard curve of the gliadin 33-mer peptide, the
main immunodominant toxic peptide in celiac patients and one of
the digestion-resistant gluten peptides [6]. The IC50 and CR were
determined for each peptide. As shown in Figure 2A, PP 24.1
peptide presented the greatest reactivity for G12/A1 antibodies.
Peptides PP 24.2, PP 24.3 and PP 22.1, were also recognized with
high sensitivity by G12 and A1. The peptide QP 22.2 showed a
drastic decrease in affinity for G12 and A1 moAbs (CR,6% for
both antibodies).
Currently, the known antibodies recognition sequences de-
scribed in toxic cereal sequences included nine different heptapep-
tides for A1 moAb, and five hexapeptides for G12 moAb [12].
Two epitopes of those 14 total sequences were found in the
identified beer peptides. Specifically, we detected the highly
reactive epitope sequences for G12 and A1, QQPFPQP and
QPQLPF respectively (Table 2) in the most reactive peptides: PP
24.1, PP 24.2, PP 24.3 and PP 22.1 (Figure 2A). However, the
QP 22.2 peptide did not show any of these G12/A1 previously
described epitopes (Figure 2A), which may explain the poor
reactivity for A1 and G12 antibodies.
We identified potential variants epitopes recognized for these
antibodies contained in these MS sequenced peptides. Thus, we
found two variants derived from the G12 epitope QPQLPF and
three derived from A1 epitope QQPFPQP with one or two
modifications in the amino acid sequences (Table 2). To
determine the relative affinity of the anti-gliadin 33-mer antibodies
for these potential epitopes present in beer peptides described, we
constructed hexa and heptapeptide variants of the G12 and A1
epitopes, respectively. The affinity of the anti-gliadin 33-mer
Figure 1. Immunogenicity of different elutions obtained by HPLC. A. Proliferative responses of PBMCs to three different elutions. B. IFN-c
production by PBMCs with three different elutions. In A and B, the results are expressed as mean 6 SD of duplicated cultures (n = 14). The
significantly differences with respect to gliadin were found at *p,0.05 and **p,0.005. Gliadin and rice prolamins were used as the positive and
negative controls, respectively. C and D. Peptide fragment identification for E6 and E17 respectively, by Mascot after mass spectrometry.
doi:10.1371/journal.pone.0100917.g001
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moAbs for different variants was determined by competitive
ELISA with immobilized gliadin in microtiter wells and was
challenged with the synthetized peptides (Table 2). For A1 moAb,
we found one different variant in the MS high reactive peptides
(PP 24.1, PP 24.2, PP 24.3 and PP 22.1), in which, a proline was
replacement by glutamine in the last position (QLPFPQQ),
showing CR of 5.59%. We found other variants of the A1
recognition sequence, QQPFPQQ and QQPFPLQ, contained in
QP 22.2 peptide that presented 30-fold lower affinity to this
antibody than those ones of the epitopes located in the high affinity
peptides. The variants studied for G12 moAb showed a dramatic
reduction in affinity. Therefore, three new reactive sequences were
identified for A1: QLPFPQQ, QQPFPLQ and QQPFPQQ. A
new sequence QPQQPF showed to be slightly recognized by G12.
In any case, there was a correlation between the epitope sequence
of the peptides and the reactivity of the anti-gliadin 33-mer moAbs
for the different peptides from the MS sequencing.
Immune stimulatory properties of the beer peptides
To determine whether the variations in the reactivity of anti-
gladin 33-mer antibodies towards the different peptides were
correlated with the immunogenicity of peptides, we determined
PBMCs stimulatory activity. Two peptides were selected, the most
reactivity peptide (PP 24.1) and the peptide with the least affinity
(QP 22.2) according to results obtained with the antibodies. The
stimulatory activity of peptides was determined by PBMC
proliferation and IFN-c production. The ability of these peptides
to induce a noxious immune response was studied in comparison
with wheat gliadin and rice prolamine as positive and negative
control, respectively. The results of cell proliferation from celiac
PBMCs clearly showed that the peptide QP 22.2 induced a weak
proliferative response (SI = 6.860.9), slightly superior to negative
control (SI = 4.760.4). Thus, we found significant differences with
regards to the cultures incubated with gliadin (SI = 21.662.4)
(Figure 3A). We could observe similar results in IFN-c production
Figure 2. Relative affinity of the anti-gliadin 33-mer monoclonal antibodies for different peptides identified. A. Amino acid sequences
of the peptides synthesized. IC50 and CR were obtained by G12 or A1 competitive ELISA. Epitope recognition of G12 and A1 moAbs are indicated by
continuous and dashed line respectively. B and C. Competitive ELISA to determine the relative affinity of these antibodies for the different peptides.
Two assays were performed, with three replicates of each.
doi:10.1371/journal.pone.0100917.g002
Table 2. Relative affinity of anti-gliadin 33-mer moAbs for different peptide variants derived from its recognition regions.
A1 moAb G12 moAb
Peptides IC50 (mg/ml) CR (%) Peptides IC50 (mg/ml) CR (%)
QLPYPQP 0.66 100.00 QPQLPY 0.23 100.00
QQPFPQP 0.17 388.23 QPQLPF 0.92 25.00
QLPFPQQ 11.79 5.59 QPQQPF 70.22 0.32
QQPFPQQ 32.08 2.05 QPQQPQ N.A N.A
QQPFPLQ 26.86 2.45
IC50 values of the antibodies to peptides are indicated. N.A.: Not applicable. Antibody epitopes described are in bold and amino acids modified are in grey and
underlined.
doi:10.1371/journal.pone.0100917.t002
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assays, where the exposure with the peptide QP 22.2 resulted in a
lower IFN-c response (6.561.1 pg/ml) with respect to high
production by cultures incubated with gliadin (26.561.6 pg/ml).
In both assays, the peptide PP 24.1 was the most immunogenic
with an increase of cell proliferation and IFN-c production
(17.561.4 and 21.561.3 pg/ml, respectively) close to those the
positive control (21.662.4 and 26.561.6 pg/ml, respectively)
(Figure 3B). These results were consistent with those earlier
obtained by competitive ELISA using anti-gliadin 33-mer
antibodies. In fact, the peptide PP 24.1 was the most potentially
immunoactive according to antibodies and cell proliferation. Thus,
a direct correlation of the moAbs reactivity and the immunoge-
nicity of peptides were corroborated.
We observed that the peptides recognized with the highest
affinity by G12/A1 moAbs showed previously described T-cell
epitopes in their sequences [25]. However, the peptide recognized
with the lowest affinity by G12 and A1 moAbs (QP 22.1), did not
show any T-cell epitopes described to date. Vader et al. (2002)
found a frequently response to nondeamidated gluten peptides,
and suggested a model where the deamidation is not a prerequisite
for the initiation of response [28]. In this work, we have shown by
in vitro studies a direct correlation of the immunogenicity of the
different nondeamidated beer peptides with the considerable
variability toxicity of peptides present in beer. We have examined
that in vitro analysis may enable identification, selection, or
production of different beer fractions with low levels of noxious
gluten proteins.
In any case, the in vitro reactivity to PBMCs of celiac patients
showed a good correlation to the reactivity of immunological
methods with the anti-gliadin 33-mer G12/A1 antibodies.
Although the diversity of peptide populations in hydrolyzed food
containing immunogenic cereals could be unlimited, the reactivity
of current methods with G12/A1 antibodies seems to react
quantitatively with those remaining peptides with potential
immunogenicity.
Future clinical studies with celiac patients would be necessary to
know which level of hydrolyzed gluten content in beer provides
reasonable safety. The underestimation of toxic gluten by those
antibodies not discriminating the immunoactivity of the peptide
might suppose an accumulative damage for celiac safety.
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